United States of America
Dr. Scott A. Rollins, Ph.D. Co-founded Alexion Pharmaceuticals Inc. in 1992 and served as its Senior Vice President for Drug Development and Project Management since September 2002. Mr. Rollins served as Chief Executive Officer and President of Selexys Pharmaceuticals Corporation and since March 1, 2008 until November 2016. He serves as the Executive Director at Tetherex Pharmaceuticals Corp. Dr. Rollins was responsible for the pre-clinical development of Alexion Pharmaceuticals Inc. anti-inflammatory compound pexelizumab since 1994. Dr. Rollins has over 16 years of experience in the discovery, development and commercialization of antibody-based drugs. Dr. Rollins has extensive experience with the FDA and led the drug development team that generated the regulatory approval filings (BLA, MAA). In addition, Dr. Rollins has managed more that 24 clinical trials and generated and filed 11 IND's. Since 1999, Dr. Rollins was additionally responsible for the project management functions of pexelizumab, under joint development with Procter & Gamble Pharmaceuticals. Dr. Rollins served as Vice President of Drug Development and Project Management of Alexion Pharmaceuticals from August 2000 to September 2002. Dr. Rollins served as Senior Director of Project Management and Drug Development from August 1999 to July 2000, Senior Director of Complement Biology from 1997 to 1999, Director of Complement Biology from 1996 to 1997, Principal Scientist from 1994 to 1996 and Staff Scientist from 1992 to 1994. Prior to 1992, Dr. Rollins was a Postdoctoral Research Fellow in the Department of Immunobiology at Yale University School of Medicine. Dr. Rollins' work has led to over 50 scientific papers and patents in the fields of complement biology. Dr. Rollins received his B.S. in Cytotechnology and Ph.D. in Microbiology and Immunology from the University of Oklahoma Health Sciences Center.